Hey Drano. You are correct, and AI will only AUGMENT the
Hey Drano. You are correct, and AI will only AUGMENT the trial process, not replace it. This is taken from a Reuters article:
Gen Li, founder of clinical data analytics firm Phesi, said many companies were exploring AI's potential to reduce the need for control groups.
Regulators, however, say that although AI has the potential to augment the clinical trial process, evidentiary standards for a drug's safety and effectiveness will not change.
"The main risks with AI are that we want to make sure we don't get the wrong answer to the question of whether a drug works," said John Concato, associate director for real-world evidence analytics in the Office of Medical Policy in the FDA's Center for Drug Evaluation and Research.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Your Rights Matter: Sage Therapeutics Shareholder Class Action If you’re an investor in Sage Therapeutics, Inc. (NASDAQ: SAGE) and have experienced significant losses, there’s a crucial opportunity for you to join a class action lawsuit against the company. The well-regarded law firm Bronstein, Gewirtz & Grossman, LLC, is informing affected shareholders about their...
Continue Reading
AI-Powered Audience Engagement Heat Index Market Overview The AI-Powered Audience Engagement Heat Index Market has witnessed impressive growth, now valued at USD 1.68 billion. Projections indicate that by 2032, this market could expand to a staggering USD 7.58 billion, representing a compound annual growth rate (CAGR) of 20.73% from 2025 to 2032. Core Components Driving...
Continue Reading
Nvidia and TSMC CEOs Share Lighthearted Banter over Dinner Nvidia Corporation (NASDAQ: NVDA) CEO Jensen Huang recently journeyed to Taiwan to engage in important discussions with CC Wei, the CEO of Taiwan Semiconductor Manufacturing Co. (NYSE: TSM). Their meeting was marked by a friendly atmosphere at dinner, where playful teasing regarding who would foot the bill took...
Continue Reading
New Gold Takes Bold Step with Tender Offer for Senior Notes New Gold Inc. has announced a tender offer targeting its 7.50% Senior Notes due 2027. This strategic move reflects the company’s commitment to optimizing its financial structure and enhancing liquidity. By conducting this tender offer, New Gold aims to reduce its debt levels and manage repayment risks more...
Continue Reading
Woolpert's New Contract to Enhance School Facilities The architecture and engineering firm Woolpert has recently been awarded an impressive five-year MATOC contract valued at $80 million. This contract aims to support the construction, maintenance, and rehabilitation of primary and secondary school facilities worldwide, specifically for military families. Collaboration...
Continue Reading
